News
RNAZ
1.350
-12.34%
-0.190
Weekly Report: what happened at RNAZ last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at RNAZ last week (1026-1030)?
Weekly Report · 11/02 09:20
TransCode Therapeutics, Inc. Initiates Strategic Process to Maximize Value of TTX-MC138 and Oncology Portfolio
NASDAQ · 10/29 08:38
TransCode Therapeutics Initiates Strategic Review of Oncology Portfolio
TipRanks · 10/28 21:21
TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138
Benzinga · 10/28 20:42
Transcode Therapeutics begins formal strategic process to evaluate opportunities
TipRanks · 10/28 20:41
*Transcode Therapeutics: Will Evaluate Strategic Alternatives Including Licensing Arrangements, Development Partnerships and Other Strategic Transactions >RNAZ
Dow Jones · 10/28 20:36
*Transcode Therapeutics: Lead Program TTX-MC138 Is in Phase 2a Clinical Development for ctDNA-positive Colorectal Cancer Following Curative-Intent Treatment >RNAZ
Dow Jones · 10/28 20:36
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
PR Newswire · 10/28 20:30
Transcode Therapeutics presents Phase 1a clinical data for TTX-MC138 in tumors
TipRanks · 10/26 11:41
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
PR Newswire · 10/26 11:31
Weekly Report: what happened at RNAZ last week (1019-1023)?
Weekly Report · 10/26 09:20
TransCode Therapeutics To Present Poster Featuring TTX-MC138 ESMO Congress 2026
Benzinga · 10/19 12:12
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
PR Newswire · 10/19 12:04
Weekly Report: what happened at RNAZ last week (1012-1016)?
Weekly Report · 10/19 09:20
Natera, TransCode Target Residual Colorectal Cancer With Trial Collaboration
NASDAQ · 10/13 13:15
Natera, Transcode to collaborate on Phase 2a trial of TTX-MC138
TipRanks · 10/13 11:40
Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer
Benzinga · 10/13 11:34
Weekly Report: what happened at RNAZ last week (1005-1009)?
Weekly Report · 10/12 09:22
Weekly Report: what happened at RNAZ last week (0928-1002)?
Weekly Report · 10/05 09:22
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.